KASRA AMIRDELFAN, M.D.

CURRENT POSITION

Boomerang Healthcare / IPM Medical Group, Inc.
1999 – Present

• Vice President of Business Development
• Director of Medical Research
• Faculty, IPM Interventional Pain Management Fellowship Program

BOARD CERTIFICATIONS

• American Board of Pain Medicine
• American Board of Family Medicine

FELLOWSHIP TRAINING

Interventional Pain Medicine
March 2000

• Pacific Pain Treatment Centers, in affiliation with California Pacific Medical Center and Stanford University, San Francisco, California

RESIDENCY

Family Medicine
July 1997

• University of Texas, Southwestern Medical School at John Peter Smith Hospital, Fort Worth, Texas

EDUCATION

M.D.

• Texas A&M University Health Sciences Center, June 1994 B.S., Microbiology & Genetics
  
• Texas A&M University, December 1989

SOCIETAL POSITIONS & LEADERSHIP

American Society of Pain & Neuroscience (ASPN)
2018 – Present

• Vice President of Clinical Affairs
• Executive Board Member
• Founding Member

Pacific Spine & Pain Society (PSPS)
2020 – Present

• Founder & Executive Board Member
• Former Vice President

California Society of Interventional Pain Physicians
2018 – 2020

• Executive Board Member

CLINICAL EXPERIENCE

Attending Physician — IPM Medical Group, Inc.
January 1999 – Present

• Multidisciplinary group practice with over 8,000 patients
• Cutting-edge surgical technology in interventional pain medicine
• Responsible for care and maintenance of all intrathecal pump patients
• Special focus on neuromodulation: spinal cord stimulators and intrathecal pump implantation

Attending Physician — Pacific Pain Treatment Centers
April 2000 – March 2001

• Full spectrum of interventional pain medicine
• Implantation of intrathecal pumps and spinal cord stimulators
• Academic teaching of incoming fellows

Physician — First Choice Health Center
September 1997 – December 1998

• Large group of Internal Medicine and Family Practice physicians
• Shared clinic and inpatient responsibilities including ICU/CCU
• Spectrum of practice included pediatrics, gynecology, and geriatrics
• Daily procedures: colposcopy, sigmoidoscopy, treadmill testing

Associate Medical Director — Foundation Health Plan
August 1998 – May 1999

• Fourth largest insurance company in the nation
• Responsible for credentialing physicians and health facilities
• Decision making for all medical appeals; served as clinical consultant
• Involved in multilevel executive policy making per Texas insurance regulations

DEPARTMENT CHAIR — PAIN MEDICINE

John Muir Medical Center
2007 – 2008

• Devised new guidelines for credentialing and granting privileges
• Developed care plan for smooth transition from inpatient to outpatient settings
• Outlined pain physician responsibilities as related to inpatient care
• Assisted in constructing an independent pain management division

Doctors' Hospital
2004 – 2006

• Directed implementation of the "5th Vital Sign" project for pain
• Helped prepare the hospital for accreditation inspection
• Assisted the hospital system in receiving its highest-ever score in pain management

INDUSTRY CONSULTANCY & SCIENTIFIC ADVISORY BOARDS

ENSO Medical
2018 – 2020

• Scientific Advisory Board — advisory on non-invasive neuromodulation devices to reduce chronic pain without opioids.

Saluda Medical
February 2016 – Present

• Scientific Advisory Board — research and development of a novel closed-loop neuromodulation device recording Evoked Compound Action Potentials (ECAP) to improve efficacy and longevity.

Nalu Medical Inc.
March 2015 – Present

• Scientific Advisory Board — research and development of a minimally invasive neuromodulation device with external generator and novel waveform.

Biotronik
August 2015 – Present

• Scientific Advisory Board — technology input, therapy concept optimization, and physician education strategy.

Medtronic Neuromodulation Division
October 2013 – 2015

• Teaching safe and effective implant techniques; education on intrathecal therapy; insight for future neuromodulation product development.

Mesoblast
November 2012 – Present

• Principal Investigator & Consultant; Scientific Advisory Board Member.

Nevro Corporation
March 2007 – Present

• Principal Investigator & Consultant; Scientific Advisory Board Member; peer-to-peer mentorship for implanting physicians.

St. Jude Neuromodulation Division
2009 – 2016

• Teaching faculty at local and national meetings; peer-to-peer development of intra-operative skills.

Boston Scientific
2007 – 2014

• Teaching faculty at local and national meetings; peer-to-peer development of intra-operative skills.

California State Medical Board
2004 – 2014

• Expert Medical Reviewer — rendered expert medical opinion regarding physician care, patient care actions, and standard of care throughout California.

Qualified Medical Evaluator
1999 – 2013

• Performed medico-legal reviews for injured workers; rendered opinions on disability, causation, apportionment, and future medical care under California Workers' Compensation guidelines.

PRINCIPAL INVESTIGATOR — CLINICAL RESEARCH PROJECTS

• Cerevu Study — 2019
  Principal Investigator. Prospective multi-center study to evaluate and measure pain levels using novel objective technology.
• Nevro Recharge Study — 2019
  Principal Investigator. Undisclosed project.
• Nevro Interface Study — 2019
  Principal Investigator. Undisclosed project.
• Biotronik Benefit-02 Study — 2018
  Principal Investigator. Prospective, multi-center, observational study evaluating subject-perceived effects of low and high frequency SCS during acute stimulation testing.
• Vertiflex Superion Registry — 2018
  Principal Investigator. Multi-center national registry to determine post-market long-term efficacy of the Superion Interspinous Spacer.
• Nevro PDN-1 Study — 2017
  Principal Investigator. Post-market study comparing 10 kHz SCS combined with conventional medical management vs. conventional medical management alone in chronic intractable neuropathic limb pain.
• Biotronik Benefit-01 Study — 2017
  Principal Investigator. Prospective, multi-center, observational study evaluating subject-perceived effects of low and high frequency SCS during acute stimulation testing.
• Saluda EVOKE Study — 2017
  Principal Investigator. Study evaluating safety and efficacy of the Saluda Medical Evoke SCS System with feedback control for chronic pain of the trunk and/or limbs.
• JointStem JSP2 — 2016
  Principal Investigator. Phase 2, double-blind, randomized, controlled study evaluating efficacy and safety of autologous adipose-derived mesenchymal stem cells for osteoarthritis.
• Nevro SENZA-ULN — 2015
  Principal Investigator. SCS study assessing safety and efficacy of the SENZA system using high-frequency stimulation for chronic neck and/or upper limb pain.
• Mesoblast DR003 — 2015
  Principal Investigator. Phase III study evaluating efficacy of stem cells for chronic low back pain due to single-level lumbar disc degeneration.
• VertiFlex STEPS Trial — 2014
  Principal Investigator. Prospective study evaluating the VertiFlex Totalis direct decompression system for lumbar spinal stenosis.
• Mallinckrodt CNS202 — 2014
  Principal Investigator. Phase III drug study evaluating safety and efficacy of intrathecal hydromorphone hydrochloride in patients with the SynchroMed II IT pump.
• St. Jude SUNBURST — 2013
  Principal Investigator. SCS study assessing safety and efficacy of the Prodigy system using BURST stimulation for chronic intractable pain of the trunk and/or limbs.
• Spinal Modulation ACCURATE — 2013
  Principal Investigator. IDE study assessing safety and efficacy of the Axium neurostimulation system for dorsal root ganglion stimulation in CRPS and peripheral causalgia.
• Mesoblast DR001 — 2012
  Principal Investigator. Phase II study using stem cells for chronic low back pain due to single-level lumbar disc degeneration.
• Nevro SENZA-RCT — 2012
  Principal Investigator. IDE study assessing safety and efficacy of the SENZA SCS system using high-frequency stimulation for chronic intractable pain of the trunk and/or limbs.
• Analysis of Contrast Spread in the Lumbar Epidural Space — 2007
  Retrospective analysis of translaminar lumbar epidural steroid injections. Outcome submitted for publication in Archives of PM&R.
• Pacific Pain Treatment Centers — Fellowship Project — 1999 – 2000
  Multi-center randomized comparative study designed to determine efficacy of translaminar vs. selective nerve root epidural steroid and local anesthetic injection.
• Private Practice, Flower Mound, Texas — Principal Investigator — 1997 – 1998
  Large, multi-center, double-blind, placebo-controlled study on otitis externa in collaboration with a major pharmaceutical company.
• Dept. of Surgery, Scott & White Hospital, Temple, TX — Sub-Investigator — 1993 – 1994
  Research on operations and demographics of the Texas EMS system; produced an overall schematic to improve regional emergency access.
• Dept. of Medical Physiology, Texas A&M University — Sub-Investigator — 1992 – 1993
  Conducted cumulative research on cystic fibrosis developments; collaborated on an overview of pathology and therapeutic methods; generated a poster presented at a Texas A&M medical symposium (April 1992).
• Dept. of Veterinary Physiology & Pharmacology, Texas A&M — 1988 – 1989
  Research Coordinator. Assisted in designing experiments with novel pharmaceuticals for acceleration of corneal healing; designed new methods to isolate rabbit neutrophils used in tissue-cultured corneas; generated data to carry program into Phase II development.
• Dept. of Medical Pathology, Texas A&M College of Medicine — 1986 – 1988
  Research Coordinator. Designed protocols to isolate renal DNA for producing monoclonal antibodies specific for renal cell carcinoma; utilized genetic engineering and electrophoretic methods; data published in the May 1990 issue of Journal of Cancer Research.

PEER-REVIEWED PUBLICATIONS

1. Grider JS, Deer TR, Beall DP, Murphy MZ, Fleming JW, Falowski SM, et al., Amirdelfan K, Sayed D. Expert opinion — pain education and early career investigators. J Pain Res. 2025;18:6651–6698.
2. Kapural L, Patel J, Rosenberg JC, Li S, Amirdelfan K, Bedder M. Musculoskeletal pain/rehabilitation and neuropathic pain. J Pain Res. 2025;18:4471–4481.
3. Lorio MP, Beall DP, Myers TJ, Naidu RK, McRoberts WP, Davis TT, Gage EG, Calodney AK, Verrills P, De Palma MJ, Amirdelfan K, Block JE. Expert opinion — musculoskeletal pain/rehabilitation. J Pain Res. 2025;18:3331–3343.
4. Costandi S, Beall DP, Davis TT, Amirdelfan K, Naidu RK, DePalma MJ, Yoon ES, Fleming JW, Block JE, Mekhail N. Durability of supplemental nucleus pulposus allograft in lumbar discogenic pain. J Vasc Interv Radiol. 2025;35(1):51–58.
5. Amirdelfan K (Kas), Provenzano D, Yu C, Verrills P, Vallejo R, Guirguis M, Tate J, Bradley K. Effects of kilohertz frequency on paresthesia perception thresholds in spinal cord stimulation. Pain Physician. 2025;28(1):E81–E91.

TEXTBOOKS & BOOK CHAPTERS

1. Beall DP, Munk PL, DePalma MJ, Davis T, Amirdelfan K (Ed.), Hunter CW (Eds.). Intrathecal Pump Drug Delivery. Medical Radiology Series. Springer Nature Switzerland AG; 2022.
2. Amirdelfan K, Silva J. High-frequency stimulation. In: Diwan S, Deer T (Eds.). Advanced Procedures for Pain Management. Springer, Cham; 2018.
3. Deer TR, Amirdelfan K, Raso LJ, Golovac S. Physician-guided lead placement: driving the lead to the target location. In: Atlas of Implantable Therapies for Pain Management. Springer; 2016.
4. Amirdelfan K, Ganesh A, Kapural L. High frequency (HF-10 therapy) for the treatment of pain in the rehabilitation patient. In: Comprehensive Pain Management in the Rehabilitation Patient. Springer; 2017.
5. Amirdelfan K. Neuromodulation. In: Integrating Pain Treatment into Your Spine Practice. Springer International; 2015.

SELECTED ABSTRACTS & POSTER PRESENTATIONS

2025

• Amirdelfan K, Chapman KB (Moderators). Abstract session: interventional pain. ASPN 7th Annual PAIN Meeting; July 2025.
• Amirdelfan K, Beall DP (Moderators). Panel: diagnosis and treatment of discogenic vs. facetogenic pain. ASPN 7th Annual PAIN Meeting; 2025.

2024

• Levy RM, Amirdelfan K, Falowski SM, Li S, Scowcroft J, Lad SP, Sayed D, Antony A, Deer TR, et al. Maximal analgesic effect attained by the use of objective neurophysiological measurements with ECAP dose-controlled closed-loop spinal cord stimulation. ASPN 6th Annual PAIN Meeting; July 11–14, 2024.
• Amirdelfan K, Petersen EA (Presenters). Session: ASPN state of science. ASPN 6th Annual PAIN Meeting; July 11–14, 2024.
• Amirdelfan K, Shah JM (Moderators). Panel: spine surgery — open, endoscopic, and percutaneous approaches. ASPN 6th Annual PAIN Meeting; July 11–14, 2024.
• Christiansen S, Amirdelfan K (Moderators). Panel: improving SCS patient outcomes. ASPN 6th Annual PAIN Meeting; July 11–14, 2024.
• Deer TR, Sayed D, Amirdelfan K (Co-chairs/Panelists). Evidence-based consensus for neurostimulation in non-surgical refractory back pain (NEURON Project). ASPN 6th Annual PAIN Meeting; July 11–14, 2024.

2023

• Petersen EA, Stauss T, Scowcroft J, Jaasma M, White J, Sills S, Amirdelfan K, Argoff C, Taylor R, Caraway D, Mekhail N. 10 kHz SCS provides durable pain relief and neurological improvements for patients with painful diabetic neuropathy: 24-month RCT results.
• Amirdelfan K. Efficacy, safety, and functional outcomes of multiphase SCS in subjects with chronic pain: BENEFIT-02 study.
• Amirdelfan K. Functional ultrasound imaging reveals activation properties of clinical spinal cord stimulation therapy.
• Verrills P, Amirdelfan K, Kapural L. First-in-human study protocol to evaluate a multiphase spinal cord stimulation system with remote device management.
• Amirdelfan K, Pope JE (Presenters). Session on ASPN NEURON project and SCS best practices.

2022

• Kapural L, Amirdelfan K, Li S, et al. Rapid return of pain upon discontinuation of commercial spinal cord stimulation systems in patients with chronic pain.
• Amirdelfan K, et al. 10 kHz SCS for the treatment of failed neck surgery syndrome: analysis of data from two multicenter studies.
• Amirdelfan K, et al. Pooled analysis of high-frequency SCS to treat neck pain in failed neck surgery syndrome patients.
• Amirdelfan K, Antony A, Levy R, et al. Patient burdens associated with spinal cord stimulation: impact of wait times to address device-related issues.
• Provenzano D, Amirdelfan K, Grewal P, et al. Modeling energy demands of a reduced-energy derivative of differential target multiplexed (DTM) stimulation.

2021

• Amirdelfan K, et al. HFX IQ data-driven, personalized pain relief.
• Sayed D, Amirdelfan K, Naidu RK, Raji OR, Falowski S. Posterior intra-articular fixation stabilizes both primary and secondary sacroiliac joints: a cadaveric study.

2019–2020

• Amirdelfan K, et al. A multicenter, prospective clinical trial of high-frequency SCS (HF-SCS) at 10 kHz in the treatment of chronic upper limb and neck pain.
• Levy R, Mekhail N, Poree L, Rosen SM, Kapural L, Amirdelfan K, et al. EVOKE: protocol design for a multicenter, prospective, randomized, double-blind study comparing ECAP-controlled closed-loop with open-loop, fixed-output SCS.

2016–2018

• Amirdelfan K, Brelje T, Spencer R. Conversion from systemic to intrathecal morphine sulfate: a case report.
• Amirdelfan K, Vallejo R, Benyamin R, et al. Spinal cord stimulation at 10 kHz for treatment of chronic upper limb and neck pain.
• Amirdelfan K, Simopoulos T, McRoberts P. Treatment of CRPS with high-frequency SCS at 10 kHz: a retrospective case series.
• Tavel E, Phillips G, Amirdelfan K, et al. Programming optimization strategies for burst SCS may improve outcomes.
• Konstantin S, North R, Deer T, Staats P, Tavel E, Amirdelfan K, et al. Burst provided sustained pain relief through 1 year.
• Tavel E, Kim C, Amirdelfan K, et al. Lower amplitudes for burst SCS programming associated with improved outcomes.

2015

• Amirdelfan K, et al. Subject satisfaction with paresthesia-free 10 kHz and paresthesia-based low-frequency SCS systems.
• Amirdelfan K, et al. Introducing the concept of remission from chronic pain.
• Kapural L, Amirdelfan K. Comparison of 10 kHz high-frequency SCS to traditional low-frequency SCS.
• Burton AW, Kapural L, Yu C, Amirdelfan K, et al. High-frequency 10 kHz stimulation produces better McGill Pain Questionnaire outcomes.
• Burton AW, Kapural L, Amirdelfan K, et al. Randomized controlled clinical trial evaluating safety and effectiveness of 10 kHz high-frequency and traditional low-frequency SCS.

2013–2014

• Amirdelfan K, et al. Remission in chronic back pain: a novel concept in SCS clinical trial results.
• Sitzman T, Kapural L, Amirdelfan K. Rationale for the SENZA-RCT study design and comparative outcomes.
• Burton A, Kapural L, Amirdelfan K. Randomized controlled clinical trial of 10 kHz high-frequency and traditional low-frequency SCS.
• Deer T, Levy R, Amirdelfan K. Prospective, randomized, multi-center, controlled clinical trial of the Spinal Modulation Axium neurostimulation system.
• Hayek S, Veizi E, Amirdelfan K. Treating difficult pain patterns with a 32-contact multiple independent current control SCS system.

2000

• Lanning RM, Krames ES, Amirdelfan K, Stevens S. The advantages and adverse effects of long-term intrathecal delivery of opioid and clonidine admixture.